Glipizide in T2DM Care - Latest Update from ADA 2024 - Video
|
Overview
The 84th Scientific Sessions of the American Diabetes Association, held in Orlando, Florida, from June 21 to June 24, 2024, featured significant discussions on diabetes management.
One of the key highlights was from a session titled "Sulfonylureas in Type 2 Diabetes Management: Should They Stay or Should They Go?". Dr. Elbert S. Huang, a prominent expert in the field, emphasized the critical role of sulfonylureas in diabetes treatment. He remarked, "Considering the broader population, sulfonylureas are essential in formularies as many T2DM patients might otherwise go untreated. With the resources needed to treat one patient with GLP-1 receptor agonists, we could treat 177 patients with sulfonylureas." This comment is particularly relevant for resource-limited settings.
Dr. Elbert Huang emphasized the careful selection of sulfonylureas to minimize risks, especially hypoglycemia. He specifically recommended short-acting variants like glipizide which offer effective glucose control at much lower costs compared to alternatives such as insulin, GLP-1 receptor agonists, and SGLT2 inhibitors. Furthermore, he advised prescribing the lowest effective dose and adjusting it based on each patient’s meal size and activity level to optimize treatment outcomes for Type 2 diabetes.
Stay tuned as we continue to bring you more updates and expert insights from the ADA sessions, shaping the future of diabetes management across the globe.
ADA supports Improving Awareness on diabetes, availability and acceSs to High quality Affordable medications for better health outcomes in countries like India.
Adapted from:
ADA 2024, Scientific Sessions, Dr. Elbert Huang, "Sulfonylureas in T2DM Management, Should They Stay or Should They Go?", June 21-24, 2024.
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
